GlaxoSmithKline has made progress with one piece of the puzzle to maintain its dominance in the respiratory drug market.
In no surprise to analysts, Novartis's QVA149 was the standout experimental drug to take the spotlight at the recent European Respiratory Society meeting in Vienna. Novartis may be delayed in the U.S. on this program, but GlaxoSmithKline hasn't been nearly as impressive with its own Relovair, a next-gen product intended to replace Advair, the top selling COPD drug.
A little more than three months since Elevation Pharmaceuticals boasted about the "gold standard" Phase IIb data generated by its nebulized LAMA product for COPD, Sunovion has stepped in to buy the company in a $430 million deal.
GlaxoSmithKline and Theravance have rolled out a battery of data from a slate of late-stage studies of their LAMA/LABA combo for COPD. And the partners say the numbers will back up their regulatory filings for the treatment beginning at the end of this year as they race promising rivals for an approval.
Today the biotech boasted that their therapy--EP-101--had registered positive data in a Phase IIb study, positioning it as a potential new "gold standard" in nebulized treatments for the ailment.
Novartis is reporting positive results from Phase III trials of QVA149, a COPD drug that uses the company's Breezhaler dry powder inhaler for delivery
GlaxoSmithKline ($GSK) is pushing ahead with its plan to submit Relovair to regulators for approval this year.
GlaxoSmithKline and Theravance have dropped another up-and-down set of data related to development of their blockbuster hopeful Relovair.
Eyeing the major market for a chronic lung condition, Forest Laboratories ($FRX) picked up the backing of an FDA panel for its experimental COPD drug known as aclidinium. It's a key endorsement...
Following a three-year review of its new approach to R&D, GlaxoSmithKline ($GSK) today revealed that it has decided to ax three of its 38 tightly-focused research units and add four more in a